• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

    5/30/23 4:35:00 PM ET
    $CTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTIC alert in real time by email

    SEATTLE, May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting of Stockholders (the "Annual Meeting") which was scheduled for June 21, 2023, and has withdrawn the proposals to have been submitted to stockholders at the Annual Meeting.

    The Annual Meeting has been cancelled due to the ongoing tender offer by Swedish Orphan Biovitrum AB (publ) (STO: SOBI) ("Sobi") to acquire all of the outstanding common stock of CTI pursuant to the Agreement and Plan of Merger, dated as of May 10, 2023, by and among Sobi, a Swedish public limited liability company, Cleopatra Acquisition Corp., a Delaware corporation and an indirect, wholly owned subsidiary of Sobi ("Purchaser"), and CTI (the "Merger Agreement"). If the transaction contemplated by the Merger Agreement is not consummated, the Board of Directors will reschedule the Annual Meeting for a later date. 

    The transaction is expected to close by the third quarter of 2023, subject to customary closing conditions. CTI expects that the current members of the Board of Directors will continue as directors until the closing of the transaction. Upon the closing of the transaction, CTI common stock will no longer be listed on any public market.

    About CTI BioPharma Corp.

    CTI BioPharma is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO® (pacritinib), a JAK2, ACVR1,­­ and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. For more information, please visit www.ctibiopharma.com.

    VONJO® is a registered trademark of CTI BioPharma Corp.

    Additional Information and Where to Find it

    The tender offer described in this press release commenced on May 25, 2023. This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of CTI common stock. On May 25, 2023, Sobi and Purchaser filed with the U.S. Securities and Exchange Commission (the "SEC") a Tender Offer Statement on Schedule TO, and CTI filed a Solicitation/Recommendation Statement on Schedule 14D-9, with respect to the tender offer. CTI STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of CTI at no expense to them. Stockholders may obtain free copies of the Tender Offer Statement and the Solicitation/Recommendation Statement, as each may be supplemented from time to time, and other documents filed by the parties at the SEC's website at www.sec.gov. Additional copies may be obtained for free by contacting Sobi or CTI. Free copies of these materials and certain other offering documents will be made available by CTI in response to requests by mail to CTI BioPharma Corp., 3101 Western Ave #800, Seattle, WA 98121, Attention: Investor Relations, by email at [email protected], or by directing requests for such materials to the information agent for the offer, which is named in the tender offer materials. Copies of the documents filed with the SEC by CTI will be available free of charge under the "Investor Relations" section of CTI's internet website at https://investors.ctibiopharma.com/.

    In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Sobi and CTI file periodic reports and other information with the SEC. Sobi's and CTI's filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

    Forward-Looking Statements

    This press release contains forward-looking statements related to CTI, Sobi and the proposed acquisition of CTI by Sobi (the "Transaction") that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "goal," "may," "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue" and similar expressions. In this press release, CTI's forward-looking statements include statements about the parties' ability to satisfy the conditions to the consummation of the tender offer and the other conditions to the consummation of the Transaction; statements about the expected timetable for completing the Transaction; and CTI's plans, objectives, expectations and intentions.

    Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of CTI's stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transaction; the effects of the Transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; that Sobi may not realize the potential benefits of the Transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies' control; transaction costs associated with the Transaction; actual or contingent liabilities; and other risks listed under the heading "Risk Factors" in CTI's periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q, and annual reports on Form 10-K, as well as the Solicitation/Recommendation Statement on Schedule 14D-9 filed by CTI and the Tender Offer Statement on Schedule TO and related tender offer documents filed by Sobi and Purchaser in connection with the Transaction. You should not place undue reliance on these statements. All forward-looking statements are based on information currently available to CTI and Sobi, and CTI and Sobi disclaim any obligation to update the information contained in this press release as new information becomes available.

    For Investors:

    Remy Bernarda

    Jenny Kobin

    [email protected] 

    (PRNewsfoto/CTI BioPharma Corp.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-cancellation-of-its-2023-annual-meeting-of-stockholders-301837725.html

    SOURCE CTI BioPharma Corp.

    Get the next $CTIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTIC

    DatePrice TargetRatingAnalyst
    10/17/2022$13.00Outperform
    SVB Leerink
    9/1/2022$13.00Buy
    Jefferies
    7/7/2022$10.00Outperform
    Cowen
    3/2/2022$4.00 → $5.00Market Outperform
    JMP Securities
    3/2/2022$5.00 → $8.00Buy
    Needham
    12/1/2021$6.00 → $5.00Buy
    Needham
    8/9/2021$7.00Buy
    BTIG Research
    More analyst ratings

    $CTIC
    Financials

    Live finance-specific insights

    See more
    • Sobi to Acquire CTI BioPharma

      Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction wi

      5/10/23 1:06:00 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

      SEATTLE, May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Registration for the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations. To participate via telephone, please register in a

      5/1/23 4:46:00 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results

      – Growing physician awareness and usage of VONJO® (pacritinib) drove quarterly double-digit revenue growth – – VONJO® net product revenue exceeded year-end goal with a total of $54 million for 2022 and $21.1 million in the fourth quarter, a 16% increase compared to the third quarter – – ASH 2022 oral presentation featured new data on pacritinib's ACVR1 inhibition and anemia benefit in myelofibrosis patients – – Management to host webcast and conference call at updated time today at 8:30 a.m. ET – SEATTLE, March 6, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for bloo

      3/6/23 6:25:00 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    SEC Filings

    See more
    • SEC Form 15-12G filed by CTI BioPharma Corp. (DE)

      15-12G - CTI BIOPHARMA CORP (0000891293) (Filer)

      7/6/23 4:15:26 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CTI BioPharma Corp. (DE)

      EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)

      6/30/23 12:15:13 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CTI BioPharma Corp. (DE)

      EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)

      6/30/23 12:15:28 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SVB Leerink initiated coverage on CTI BioPharma with a new price target

      SVB Leerink initiated coverage of CTI BioPharma with a rating of Outperform and set a new price target of $13.00

      10/17/22 7:38:54 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on CTI BioPharma with a new price target

      Jefferies initiated coverage of CTI BioPharma with a rating of Buy and set a new price target of $13.00

      9/1/22 7:25:53 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on CTI BioPharma with a new price target

      Cowen initiated coverage of CTI BioPharma with a rating of Outperform and set a new price target of $10.00

      7/7/22 7:34:10 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by CTI BioPharma Corp. (DE) (Amendment)

      SC 13D/A - CTI BIOPHARMA CORP (0000891293) (Subject)

      6/28/23 1:51:34 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CTI BioPharma Corp. (DE)

      SC 13G - CTI BIOPHARMA CORP (0000891293) (Subject)

      4/14/23 8:25:50 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CTI BioPharma Corp. (DE)

      SC 13G - CTI BIOPHARMA CORP (0000891293) (Subject)

      3/24/23 4:49:08 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION. STOCKHOLM, June 24, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) announced today that it has, through its indirect wholly owned subsidiary Cleopatra Acquisition Corp. (Cleopatra), successfully completed its tender offer to purchase all outstanding shares of common stock of CTI BioPharma Corp. (NASDAQ:CTIC) (CTI), at a price of USD 9.10 per sh

      6/24/23 6:49:00 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

      SEATTLE, May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting of Stockholders (the "Annual Meeting") which was scheduled for June 21, 2023, and has withdrawn the proposals to have been submitted to stockholders at the Annual Meeting. The Annual Meeting has been cancelled due to the ongoing tender offer by Swedish Orphan Biovitrum AB (publ) (STO: SOBI) ("Sobi") to acquire all of the outstanding common stock of CTI pursuant to the Agreement and Plan of Merger, dated as of M

      5/30/23 4:35:00 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sobi to Acquire CTI BioPharma

      Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction wi

      5/10/23 1:06:00 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Celularity Appoints Industry Leader Diane Parks to its Board of Directors

      FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

      6/3/22 8:00:00 AM ET
      $CALT
      $CELU
      $CTIC
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors

      SEATTLE, Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Amgen, and Genentech. "Diane is an accomplished leader with considerable experience driving the successful planning, launch, and commercialization of new medicines in hematology and oncology," said Laurent Fischer, M.D., Chairman of the Board of CTI Biopharma. "We are pleased to have Diane join CTI's Board of Directors at this pivotal time as we advance our JAK2/IRAK-1 inhibitor pacritinib towards a po

      8/24/21 7:00:00 AM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Bvf Partners L P/Il

      4 - CTI BIOPHARMA CORP (0000891293) (Issuer)

      6/28/23 6:26:13 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Parks Diane L.

      4 - CTI BIOPHARMA CORP (0000891293) (Issuer)

      6/26/23 4:05:38 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Fischer Laurent

      4 - CTI BIOPHARMA CORP (0000891293) (Issuer)

      6/26/23 4:05:31 PM ET
      $CTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care